Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-2.15bn
- Incorporated2016
- Employees14.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kringle Pharma Inc | 72.62m | -905.42m | 2.77bn | 17.00 | -- | 2.21 | -- | 38.15 | -130.95 | -130.95 | 10.48 | 170.57 | 0.032 | -- | 1.01 | 4,272,000.00 | -39.93 | -23.52 | -42.03 | -24.93 | -- | -- | -1,246.73 | -349.89 | 16.65 | -3,738.20 | 0.00 | -- | -9.77 | -31.17 | -21.13 | -- | -- | -- |
| Veritas In Silico Inc | 91.14m | -425.67m | 3.16bn | 19.00 | -- | 1.77 | -- | 34.66 | -65.62 | -65.62 | 14.05 | 274.99 | 0.0441 | -- | 6.11 | -- | -20.59 | -- | -21.32 | -- | -- | -- | -467.05 | -- | 18.35 | -- | -- | -- | -53.18 | -- | -80.03 | -- | -- | -- |
| NPT Co Ltd | 0.00 | -266.47m | 3.41bn | 7.00 | -- | 43.82 | -- | -- | -54.98 | -54.98 | 0.00 | 15.98 | 0.00 | -- | -- | 0.00 | -318.44 | -- | -439.04 | -- | -- | -- | -- | -- | -- | -2,152.88 | 0.00 | -- | -- | -- | -68.67 | -- | -- | -- |
| FunPep Co Ltd | 314.00k | -1.91bn | 3.77bn | 15.00 | -- | 2.58 | -- | 12,014.12 | -51.03 | -51.03 | 0.0083 | 36.09 | 0.0001 | -- | -- | -- | -75.09 | -37.74 | -92.91 | -41.17 | -- | -- | -608,766.90 | -4,142.72 | 3.71 | -- | -- | -- | -94.88 | -36.20 | -115.00 | -- | -- | -- |
| Ribomic Inc | 750.00k | -1.04bn | 4.46bn | 25.00 | -- | 1.38 | -- | 5,940.37 | -22.23 | -22.23 | 0.0159 | 59.35 | 0.0002 | -- | 0.0173 | 30,000.00 | -31.47 | -29.95 | -32.94 | -31.15 | -- | -- | -138,954.00 | -2,725.95 | 20.66 | -- | 0.00 | -- | -- | -55.55 | 0.5173 | -- | -6.86 | -- |
| Human Metabolome Technologies Inc | 1.43bn | 207.06m | 4.48bn | 62.00 | 21.34 | 2.35 | 14.02 | 3.13 | 35.42 | 35.42 | 248.83 | 321.25 | 0.6237 | 10.29 | 4.91 | 23,060,290.00 | 9.03 | 10.54 | 10.98 | 13.59 | 60.48 | 66.65 | 14.48 | 17.24 | 5.13 | 391.35 | 0.0555 | 20.98 | 8.12 | 5.40 | 5.42 | -- | 33.68 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.15bn | 5.16bn | 14.00 | -- | 1.83 | -- | -- | -28.13 | -28.13 | 0.00 | 32.23 | 0.00 | -- | -- | -- | -64.69 | -47.62 | -67.23 | -49.48 | -- | -- | -- | -22,365.60 | -- | -- | -- | -- | -- | -- | -63.34 | -- | -68.51 | -- |
| D.Western Therapeutics Institute Inc | 387.62m | -632.09m | 5.48bn | 21.00 | -- | 3.82 | -- | 14.14 | -13.31 | -13.31 | 8.09 | 26.46 | 0.2019 | 0.4115 | 3.53 | -- | -32.93 | -28.15 | -36.09 | -30.68 | 89.97 | 92.09 | -163.07 | -155.99 | 9.48 | -- | 0.2966 | -- | -17.80 | 1.74 | 51.01 | -- | -11.74 | -- |
| TMS Co Ltd | 0.00 | -670.20m | 6.23bn | 18.00 | -- | 2.08 | -- | -- | -15.72 | -15.72 | 0.00 | 65.78 | 0.00 | -- | -- | 0.00 | -21.59 | -- | -22.41 | -- | -- | -- | -- | -- | 23.99 | -- | 0.00 | -- | -- | -- | 31.20 | -- | -- | -- |
| Carna Biosciences, Inc. | 579.06m | -2.17bn | 6.43bn | 63.00 | -- | 20.80 | -- | 11.11 | -113.62 | -113.62 | 30.30 | 16.16 | 0.2894 | 1.24 | 6.17 | -- | -108.53 | -37.21 | -120.28 | -41.98 | 67.03 | 86.49 | -375.00 | -118.28 | 6.08 | -75.55 | 0.6979 | -- | -8.99 | -12.57 | 0.3262 | -- | -33.02 | -- |
| Noile-Immune Biotech Inc | 7.14m | -782.47m | 6.67bn | 25.00 | -- | 1.62 | -- | 933.57 | -18.07 | -18.07 | 0.165 | 95.16 | 0.0016 | 0.00 | 0.0668 | 285,720.00 | -17.08 | -- | -17.32 | -- | 30.00 | -- | -10,954.38 | -- | 60.62 | -- | 0.00 | -- | -97.61 | -- | 14.65 | -- | -- | -- |
| Cyfuse Biomedical KK | -100.00bn | -100.00bn | 6.75bn | 21.00 | -- | 2.36 | -- | -- | -- | -- | -- | 286.90 | -- | -- | -- | -- | -- | -13.87 | -- | -16.49 | -- | 68.61 | -- | -178.86 | 4.44 | -- | 0.3224 | -- | 324.27 | 10.94 | 12.43 | -- | 182.58 | -- |
| Tsubota Laboratory Inc | 710.56m | -398.77m | 6.86bn | 17.00 | -- | 6.21 | -- | 9.66 | -15.53 | -15.53 | 27.55 | 42.86 | 0.3594 | 0.4522 | 50.46 | 41,797,700.00 | -20.17 | 0.1041 | -29.56 | 0.1517 | 81.65 | 71.43 | -56.12 | 0.2216 | 2.60 | -- | 0.0634 | 0.00 | 101.49 | 25.17 | 132.08 | 132.70 | 26.42 | -- |
| Chiome Bioscience Inc | 593.29m | -982.78m | 7.64bn | 47.00 | -- | 6.71 | -- | 12.88 | -14.48 | -14.48 | 8.74 | 16.39 | 0.2828 | 4.97 | 9.64 | -- | -46.84 | -52.22 | -59.06 | -64.41 | 59.93 | 57.59 | -165.65 | -174.88 | 3.99 | -1,177.61 | 0.1891 | -- | -24.02 | 4.29 | 3.72 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Modalis Therapeutics Corp's reporting currency: Japanese Yen JPY
3.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evolution Capital Management LLCas of 26 Jan 2026 | 3.20m | 3.69% |
| Amova Asset Management Co., Ltd.as of 22 Apr 2024 | 0.00 | 0.00% |
Data from 31 Dec 2025 - 04 Feb 2026Source: FactSet Research Systems Inc.
